Gilead(GILD) ZACKS·2025-02-04 16:05Company Overview - Gilead Sciences (GILD) is anticipated to report a year-over-year decline in earnings due to lower revenues for the quarter ended December 2024, with earnings expected to be 7.06 billion, down 0.8% from the previous year [1][3]. Earnings Expectations - The earnings report is scheduled for release on February 11, 2025, and could influence the stock price positively if results exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 9.53% higher in the last 30 days, indicating a more favorable outlook from analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP (Expected Surprise Prediction) model suggests that Gilead has a positive Earnings ESP of +2.30%, indicating a likelihood of beating the consensus EPS estimate [10][11]. - Gilead currently holds a Zacks Rank of 3 (Hold), which, when combined with the positive Earnings ESP, suggests a higher probability of an earnings beat [11]. Historical Performance - In the last reported quarter, Gilead exceeded the expected earnings of 2.02, resulting in a surprise of +27.85% [12]. - Over the past four quarters, Gilead has surpassed consensus EPS estimates three times [13]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Vertex Pharmaceuticals (VRTX) is also expected to report earnings of 2.77 billion, up 10% from the previous year [17]. - Vertex has an Earnings ESP of 0.77% and a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate as well [18].